Core Insights - The Beijing pharmaceutical and health industry reached a scale of 1.06 trillion yuan in 2024, with a year-on-year growth of 8.7%, indicating a significant acceleration towards becoming a globally influential modern pharmaceutical and health industry cluster [1] Group 1: Industry Development - The Beijing municipal government has implemented three rounds of action plans since 2018 to accelerate collaborative innovation in the pharmaceutical and health sector, establishing a dual leadership mechanism between technology management and industry management departments [1][2] - In 2024 and 2025, Beijing introduced measures to promote high-quality development in the pharmaceutical sector, attracting eight well-known pharmaceutical companies to establish innovative entities in the city [2] Group 2: Talent and Investment - The city has initiated various talent training programs, including those for physician-scientists and young clinical research talents, to effectively cultivate urgently needed professionals in the industry [2] - A municipal-level investment fund of 20 billion yuan has been established to support innovation and development in the pharmaceutical and health sector [2] Group 3: Technological Advancements - Beijing boasts a concentration of technological resources, including universities and research institutions, which support the design and modification of microorganisms, leading to innovative outcomes in key technology areas [3] - The city has a leading clinical level with numerous national clinical research centers and medical centers, housing expert teams with extensive clinical experience [3] Group 4: Emerging Industries - Significant progress has been made in brain-machine interface and synthetic biology manufacturing, with breakthroughs in key technologies and clinical applications [4][5] - The development of innovative products, such as the world's first efficient large fragment DNA insertion technology and advanced biomanufacturing techniques, has been achieved [5] Group 5: Future Directions - Moving forward, Beijing aims to enhance policy implementation and promote innovation-driven industry development, focusing on brain-machine interfaces and synthetic biology manufacturing to foster new productive forces [6]

Core Viewpoint - China has reached a world-leading level in semi-invasive brain-computer interface (BCI) technology, with invasive BCI technology also accelerating towards catching up, particularly in the medical field for patients with major motor disorders [1][2]. Group 1: Technology Development - The semi-invasive intelligent brain-computer system "Beijing Brain No. 1" has completed two batches of five human implants, showing initial recovery effects in subjects, and is preparing for formal clinical trials [1][7]. - "Beijing Brain No. 1" is the first international system to achieve over 100 channels, high throughput, wireless full implantation, and near-practical application [5]. - "Beijing Brain No. 2" has achieved the first international success in enabling a monkey to intercept a moving target using thought, with plans for clinical validation next year [10][11]. Group 2: Patient Impact - The initial focus for "Beijing Brain No. 1" is on patients with paralysis and speech disorders, with the potential to help restore communication abilities for speech-impaired patients [2][8]. - Among the five patients implanted, one with speech impairment has achieved a 63% accuracy in decoding 62 words, demonstrating the system's capability to assist in communication [8]. - The other four patients, suffering from various motor function disorders, have shown improvements in rehabilitation, such as enhanced muscle strength and the ability to control mechanical arms [8][9]. Group 3: Market and Competition - China has become the second country globally, after the United States, to enter the clinical trial phase for invasive BCI technology [2]. - The competitive landscape in China's invasive BCI market is expected to accelerate technological advancements, although there is still a gap compared to global leaders like Neuralink, which supports up to 1024 channels [12]. - The establishment of Beijing Brain Institute and the company Chip Intelligence is aimed at promoting the commercialization of BCI technologies and integrating resources for more effective research and development [4][12].

李园解释说，128通道即有128个采集信号的触点，触点越多，采集的信息量就越大。电极上设计更多触 点并非难点，但多信号同时处理时，无线传输和处理器如何保证高通量、低功耗是系统的难度所 在。"北脑一号"实现了全球同类脑机产品的最大信号通量，信号采集精度、信号传输和处理性能均处在 世界先进水平。 屏幕上显现出一道道起伏波动的线条。"患者想动左手还有右手，或者处在静息状态时，脑电信号的特 征都是不一样的。我们用神经编解码算法解读特征，再把它转换成控制指令，驱动患者的外骨骼。"系 统能够帮助因脊髓损伤、脑卒中、渐冻症等创伤或疾病导致运动或言语障碍的患者，实现运动和言语功 能的替代和康复。 如今距离手术完成已超过3个月，患者除了能够用"意念"控制机械臂、电脑光标外，上肢也逐步呈现康 复进展，能够完成术前不能完成的一些手部动作，例如手指捏放玻璃弹珠等。 6月19日，记者从"活力中国调研行"采访活动中获悉，北京脑科学与类脑研究所和北京芯智达神经技术 有限公司合作研制的"北脑一号"智能脑机系统已完成国际首批柔性高通量半侵入式无线全植入脑机系统 的人体植入，进入临床验证阶段，目前已完成5例患者植入，为脊髓损伤、脑卒中、渐冻症患 ...

丨证券研究报告丨 行业研究丨点评报告丨软件与服务 [Table_Title] 侵入式脑机接口临床试验成功，我国脑机接口进 入新阶段 报告要点 [Table_Summary] 近日，中国科学院脑科学与智能技术卓越创新中心联合复旦大学附属华山医院，与相关企业合 作，成功开展了我国首例侵入式脑机接口的前瞻性临床试验。该成果标志着我国在侵入式脑机 接口技术上成为全球第二个进入临床试验阶段的国家。另一方面，美股脑机接口概念股脑再生 科技(RGC)股价在 6 月 16 日大幅上涨，接连触发多次熔断，最后报收 60 美元，涨幅高达 283.12%。建议关注三条主线：1、侵入式脑机接口海外先进产业链的国内映射标的；2、非侵 入式脑机接口在消费场景的产品落地相关标的；3、脑机接口下游应用端相关标的。 近日，中国科学院脑科学与智能技术卓越创新中心联合复旦大学附属华山医院，与相关企业合 作，成功开展了我国首例侵入式脑机接口的前瞻性临床试验。该成果标志着我国在侵入式脑机 接口技术上成为全球第二个进入临床试验阶段的国家。另一方面，美股脑机接口概念股脑再生 科技(RGC)股价在 6 月 16 日大幅上涨，接连触发多次熔断，最后报收 60 ...

2025.6.18 市场逻辑精选 特别提示：下文涉及的题材或公司，内容罗列和篇幅长短，与后续涨跌无关，亦均非进行推荐，仅作- 研究辅助。投资者应自主决策,注意风险。 市场热点 , 脑机接口:美股脑再生科技今年涨超460倍,国内行业进展加速 。 驱动: 。中游算法/设备核心公司: 。下游应用核心公司: 二、机会前瞻 新质战斗力:地缘冲突频发,军贸出口受益 份额有望持续提升。 期货:陆家嘴论坛召开在即 三、大涨分析 赢合科技:固态电池交付头部客户 恒基达鑫:原油价格波动带动油运仓储价格上涨 石化仓储：公司核心业务为散装液体仓储，利用自建的储罐、管道、码头及槽罐车装卸台，为客户提- 供汽油、柴油、液化气等综合仓储服务，在珠三角、长三角和华中地区拥有先进的仓储及码头设施,- 是华南及华东地区石化产品仓储的知名企业。 科力远:布局硫化物固态电解质,参编RWA上链技术规范 英派斯:投资李未可,深耕智能运动装备领域 三夫户外:国内户外装备零售龙头 主营户外品牌：公司打造"自有品牌+独家代理品牌"的品牌矩阵，拥有XBIONIC、X-SOCKS等自有品- 牌,独家代理CRISPI、HOUDINI、DANNER等国际户外品牌,经 ...

聚焦股权投资行业人物、事件、数据、研究、政策解读，提供专业视角和深度洞见 | 创投圈有趣的灵魂 以下文章来源于东四十条资本 ，作者刘燕秋 东四十条资本 . 将投中网设为"星标⭐"，第一时间收获最新推送 0营收的中药公司，搭上"脑机接口"起飞。 作者丨 刘燕秋 来源丨 东四十条资本 这家神奇的公司还得从创始人说起。根据公司官网信息，区逸基，Regencell创始人兼首席执行官，毕业于加州大学伯克利分 校哈斯商学院。获得学士学位后，他投身投资银行领域，先后就职于德意志银行和巴林银行。 在职业生涯中，区逸基成果斐然，完成超 40 亿美元交易，荣获多项重要并购奖项。他的代表交易包括代表第一太平有限公 司，以7.5亿美元收购菲律宾长途电话公司、6.5亿美元收购Indofood，以及完成 Hagemeyer 40% 股权18亿美元的增发 。 此外，他还是房地产、科技和生物科技领域的活跃投资者。 然而这位青年才俊的成长之路并非一帆风顺。童年时期，区逸基因患有注意力缺陷多动障碍（ADHD）和自闭症（ASD）。受 病症影响，他脾气暴躁，在学校备受孤立，成绩也不理想，高中时成绩甚至排倒数。为完成学业，他每天都需花费远超常人的 时 ...

脑机接口概念股震荡反弹 创新医疗涨停 智通财经6月19日电，创新医疗涨停，爱朋医疗涨超5%，南京熊猫、汉威科技、荣泰健康、倍益康、国 际医学等跟涨。消息面上，中国科学院脑科学与智能技术卓越创新中心近日联合复旦大学附属华山医 院，与相关企业合作，成功开展了我国首例侵入式脑机接口的前瞻性临床试验。 ...

这几只票暗盘资金正在偷偷流入，立即查看>> 脑机接口板块直线拉升，创新医疗（002173）涨停，倍益康、爱朋医疗（300753）、南京熊猫 （600775）、熵基科技（301330）、三博脑科（301293）等纷纷走高。 ...

Core Insights - The strategic partnership between UCloud and BrainTiger Technology focuses on invasive brain-machine interfaces, achieving significant results in high-precision real-time motion decoding clinical trials [1] Group 1: Clinical Trial Achievements - BrainTiger Technology, in collaboration with the Shanghai Institute of Microsystem and Information Technology of the Chinese Academy of Sciences, successfully implanted a self-developed 256-channel flexible brain-machine interface in a 19-year-old patient with right frontal lobe epilepsy [1] - The subject demonstrated precise brain control over classic games such as "Pac-Man" and "Tank Battle," as well as complex games like "Honor of Kings" and "Black Myth: Wukong" [1] - The patient was also able to smoothly browse the internet and operate various apps (e.g., Bilibili, Xiaohongshu), control a smart wheelchair, and manage smart home devices (lighting, curtains, etc.) [1] - Throughout the clinical trial, the subject's condition remained stable and healthy [1]

Group 1 - The People's Bank of China announced eight significant financial opening measures, leading to a slight increase in major A-share indices, with the Shanghai Composite Index rising by 0.04% to 3388 points and the Shenzhen Component Index increasing by 0.24% [1] - The total trading volume for the day was 1.22 trillion yuan, which is a decrease of 15.4 billion yuan compared to the previous trading day, with nearly 3500 stocks declining across the market [1] Group 2 - The PCB and electronic components sectors saw gains, with companies like Huadian Co., Ltd. (002463) hitting the daily limit, and the storage chip sector also surged, with Kexiang Co., Ltd. reaching a 20% limit up [3] - The blind box economy sector experienced a downturn, with Yuanlong Yatu (002878) dropping over 8%, while the pesticide and veterinary drug sectors also fell, with Sulihua Co., Ltd. (603585) hitting the daily limit down [3]